PET and PET–CT imaging of gynecological malignancies: present role and future promise

References

• Long HJ 3rd. Management of metastatic cervical cancer: review of the literature. J. Clin. Oncol.25(20), 2966–2974 (2007).
   PubMedGoogle Scholar
• Pazdur R, Coia LR, Hoskins WJ, Wagman LD (Eds). Cancer Management: a Multidisciplinary Approach (4th Edition). PRR Inc. NY, USA 361–430 (1999).
   Google Scholar
• Syrjänen K. Mechanisms and predictors of high-risk human papillomavirus (HPV) clearance in the uterine cervix. Eur. J. Gynaecol. Oncol.28(5), 337–351.
   Google Scholar
• Alvarez-Salas LM, DiPaolo JA. Molecular approaches to cervical cancer therapy. Curr. Drug Discov. Technol.4(3), 208–219 (2007).
   Google Scholar
• Koyama T, Tamai K, Togashi K. Staging of carcinoma of the uterine cervix and endometrium. Eur. Radiol.17(8), 2009–2019 (2007).
   PubMed Web of Science ®Google Scholar
• Pecorelli S, Ngan HYS, Hacker NF (Eds). Staging Classifications and Clinical Practice Guidelines for Gynaecological Cancers. A Collaboration Between FIGO and IGCS. (3rd Edition). FIGO, London, UK (2006).
   Google Scholar
• Heller PB, Malfetano JH, Bundy BN, Barnhill DR, Okagaki T. Clinical-pathologic study of stage IIB, III, and IVA carcinoma of the cervix: extended diagnostic evaluation for para-aortic node metastasis – a Gynecologic Oncology Group study. Gynecol. Oncol.38(3), 425–430 (1990).
   PubMed Web of Science ®Google Scholar
• Hricak H, Lacey CG, Sandles LG, Chang YC, Winkler ML, Stern JL. Invasive cervical carcinoma: comparison of MR imaging and surgical findings. Radiology166, 623–631 (1988).
   PubMed Web of Science ®Google Scholar
• Delgado G, Bundy B, Zaino R, Sevin BU, Creasman WT, Major F. Prospective surgical–pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol. Oncol.38(3), 352–357 (1990).
   PubMed Web of Science ®Google Scholar
• Sevin BU, Lu Y, Bloch DA, Nadji M, Koechli OR, Averette HE. Surgically defined prognostic parameters in patients with early cervical carcinoma. A multivariate survival tree analysis. Cancer78(7), 1438–1446 (1996).
   PubMed Web of Science ®Google Scholar
• Sahdev A, Sohaib SA, Wenaden AE, Shepherd JH, Reznek RH. The performance of magnetic resonance imaging in early cervical carcinoma: a long-term experience. Int. J. Gynecol. Cancer17(3), 629–636 (2007).
   PubMed Web of Science ®Google Scholar
• Belhocine A, Thille V, Fridman A et al. Contribution of whole-body 18FDG PET imaging in the management of cervical cancer. Gynecol. Oncol.87(1), 90–97 (2002).
   Google Scholar
• Grigsby PW, Dehdashti F, Siegel BA. FDG-PET Evaluation of carcinoma of the cervix. Clin. Positron Imaging2(2), 105–109 (1999).
   Google Scholar
• Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J. Clin. Oncol.19(17), 3745–3749 (2001).
   PubMed Web of Science ®Google Scholar
• Grigsby PW, Siegel BA, Dehdashti F, Mutch DG. Posttherapy surveillance monitoring of cervical cancer by FDG-PET. Int. J. Radiat. Oncol. Biol. Phys.55(4), 907–913 (2003).
   PubMed Web of Science ®Google Scholar
• Wong TZ, Jones EL, Coleman RE. Positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol. Imaging Biol.6, 55–62 (2004).
   PubMed Web of Science ®Google Scholar
• Tran BN, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. Occult supraclavicular lymph node metastasis identified by FDG-PET in patients with carcinoma of the uterine cervix. Gynecol. Oncol.90, 572–576 (2003).
   PubMed Web of Science ®Google Scholar
• Hope AJ, Saha P, Grigsby PW. FDG-PET in carcinoma of the uterine cervix with endometrial extension. Cancer106(1), 196–200 (2006).
   Google Scholar
• Wright JD, Dehdashti F, Herzog TJ et al. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucose-positron emission tomography. Cancer104(11), 2484–2491 (2005).
   PubMed Web of Science ®Google Scholar
• Sironi S, Buda A, Picchio M et al. Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/CT. Radiology238(1), 272–279 (2006).
   PubMed Web of Science ®Google Scholar
• Bjurberg M, Kjellén E, Ohlsson T, Ridderheim M, Brun E. FDG-PET in cervical cancer: staging, re-staging and follow-up. Acta Obstet. Gynecol. Scand.86(11), 1385–1391 (2007).
   Web of Science ®Google Scholar
• Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol. Oncol.97(1), 183–191 (2005).
   PubMed Web of Science ®Google Scholar
• Kerr IG, Manji MF, Powe J, Bakheet S, Al Suhaibani H, Subhi J. Positron emission tomography for the evaluation of metastases in patients with carcinoma of the cervix: a retrospective review. Gynecol. Oncol.81(3), 477–480 (2001).
   Google Scholar
• Yen TC, See LC, Lai CH et al. Standardized uptake value in para-aortic lymph nodes is a significant prognostic factor in patients with primary advanced squamous cervical cancer. Eur. J. Nucl. Med. Mol. Imaging35(3), 493–501. (2008).
   Google Scholar
• Kidd EA, Siegel BA, Dehdashti F, Grigsby PW. The standardized uptake value for F-18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survival. Cancer110(8), 1738–1744 (2007).
   PubMed Web of Science ®Google Scholar
• Xue F, Lin LL, Dehdashti F, Miller TR, Siegel BA, Grigsby PW. F-18 fluorodeoxyglucose uptake in primary cervical cancer as an indicator of prognosis after radiation therapy. Gynecol. Oncol.101(1), 147–151 (2006).
   PubMed Web of Science ®Google Scholar
• Yen TC, See LC, Lai CH et al.18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression. J. Nucl. Med.45(1), 22–29 (2004).
   PubMed Web of Science ®Google Scholar
• Singh AK, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int. J. Radiat. Oncol. Biol. Phys.56(2), 489–493 (2003).
   PubMed Web of Science ®Google Scholar
• Lin LL, Yang Z, Mutic S, Miller TR, Grigsby PW. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. Int. J. Radiat. Oncol. Biol. Phys.65(1), 177–181 (2006).
   Google Scholar
• Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J. Clin. Oncol.22(11), 2167–2171 (2004).
   PubMed Web of Science ®Google Scholar
• Lin LL, Mutic S, Malyapa RS et al. Sequential FDG-PET brachytherapy treatment planning in carcinoma of the cervix. Int. J. Radiat. Oncol. Biol. Phys.63(5), 1494–1501 (2005).
   PubMedGoogle Scholar
• Chang WC, Hung YC, Lin CC, Shen YY, Kao CH. Usefulness of FDG-PET to detect recurrent cervical cancer based on asymptomatically elevated tumor marker serum levels – a preliminary report. Cancer Invest.22(2), 180–184 (2004).
   PubMed Web of Science ®Google Scholar
• Lapela M, Leskinen-Kallio S, Varpula M et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J. Nucl. Med.35, 1618–1623 (1994).
   PubMed Web of Science ®Google Scholar
• Torizuka T, Kanno T, Futatsubashi M et al. Imaging of gynecologic tumors: comparison of (11)C-choline PET with (18)F-FDG PET. J. Nucl. Med.44, 1051–1056 (2003).
   PubMed Web of Science ®Google Scholar
• Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J. Nucl. Med.49(7), 1177–1182 (2008).
   PubMed Web of Science ®Google Scholar
• Nahhas WA. Ovarian cancer: current outlook on this deadly disease. Postgrad. Med.102, 112–120 (1997).
   PubMed Web of Science ®Google Scholar
• Young RC, Fuks Z, Hoskins WJ. Cancer of the ovary. In: Cancer: Principles and Practice of Oncology (6th Edition). Devita VT, Hellman S, Rosenberg SA (Eds). JB Lippincott Co., PA, USA (2001).
   Google Scholar
• Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomography (PET) using 2-[18F]deoxyglucose (2-[18F]FDG). Gynecol. Oncol.51, 197–204 (1993).
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Kurokawa T, Kawahara K et al. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. AJR Am. J. Roentgenol.182, 227–233 (2004).
   PubMed Web of Science ®Google Scholar
• Schroder W, Zimny M, Rudlowski C, Bull U, Rath W. The role of 18-F-flurorodeoxyglucose position imaging tomography 18-F-FGD PET in ovarian carcinoma. Int. J. Gynecol. Cancer.9, 117–122 (1999).
   PubMed Web of Science ®Google Scholar
• Römer W, Avril N, Dose J et al. [Metabolic characterization of ovarian tumors with positron-emission tomography and F-18 fluorodeoxyglucose]. Rofo166(1), 62–68 (1997).
   PubMedGoogle Scholar
• Zimny M, Schröder W, Wolters S, Cremerius U, Rath W, Büll U. [18F-fluorodeoxyglucose PET in ovarian carcinoma: methodology and preliminary results]. Nuklearmedizin36(7), 228–233 (1997).
   Google Scholar
• Rieber A, Nüssle K, Stöhr I et al. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. AJR Am. J. Roentgenol.177(1), 123–129 (2001).
   PubMed Web of Science ®Google Scholar
• Risum S, Høgdall C, Loft A et al. The diagnostic value of PET/CT for primary ovarian cancer – a prospective study. Gynecol. Oncol.105(1), 145–149 (2007).
   PubMed Web of Science ®Google Scholar
• Risum S, Høgdall C, Loft A et al. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography – a prospective study. Gynecol. Oncol.108(2), 265–270 (2008).
   PubMedGoogle Scholar
• Rose PG, Faulhaber P, Miraldi F, Abdul-Karim FW. Positive emission tomography for evaluating a complete clinical response in patients with ovarian or peritoneal carcinoma: correlation with second-look laparotomy. Gynecol. Oncol.82, 17–21 (2001).
   Google Scholar
• Drieskens O, Stroobants S, Gysen M, Vandenbosch G, Mortelmans L, Vergote I. Positron emission tomography with FDG in the detection of peritoneal and retroperitoneal metastases of ovarian cancer. Gynecol. Obstet. Invest.55, 130–134 (2003).
   Google Scholar
• Gu P, Pan LL, Wu SQ, Sun L, Huang G. CA 125, PET alone, PET–CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur. J. Radiol. DOI: 10.1016/j.ejrad.2008.02.019 (2008) (Epub ahead of print).
   Google Scholar
• Murakami M, Miyamoto T, Iida T et al. Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer. Int. J. Gynecol. Cancer16(Suppl. 1), 99–107 (2006).
   Google Scholar
• Kubik-Huch RA, Dörffler W, von Schulthess GK et al. Value of (18F)-FDG positron emission tomography, computed tomography, and magnetic resonance imaging in diagnosing primary and recurrent ovarian carcinoma. Eur. Radiol.10(5), 761–767 (2000).
   PubMed Web of Science ®Google Scholar
• Nakamoto Y, Saga T, Ishimori T et al. Clinical value of positron emission tomography with FDG for recurrent ovarian cancer. AJR Am. J. Roentgenol.176(6), 1449–1454 (2001).
   PubMed Web of Science ®Google Scholar
• Hauth EA, Antoch G, Stattaus J et al. Evaluation of integrated whole-body PET/CT in the detection of recurrent ovarian cancer. Eur. J. Radiol.56(2), 263–268 (2005).
   PubMed Web of Science ®Google Scholar
• Jiménez-Bonilla J, Maldonado A, Morales S et al. Clinical impact of 18F-FDG-PET in the suspicion of recurrent ovarian carcinoma based on elevated tumor marker serum levels. Clin. Positron Imaging3(6), 231–236 (2000).
   Google Scholar
• Yen RF, Sun SS, Shen YY, Changlai SP, Kao A. Whole body positron emission tomography with 18F-fluoro-2-deoxyglucose for the detection of recurrent ovarian cancer. Anticancer Res.21(5), 3691–3694 (2001).
   PubMed Web of Science ®Google Scholar
• Torizuka T, Nobezawa S, Kanno T et al. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy-D-glucose. Eur. J. Nucl. Med. Mol. Imaging29(6), 797–803 (2002).
   PubMed Web of Science ®Google Scholar
• Cho SM, Ha HK, Byun JY et al. Usefulness of FDG PET for assessment of early recurrent epithelial ovarian cancer. AJR Am. J. Roentgenol.179(2), 391–395 (2002).
   PubMed Web of Science ®Google Scholar
• Nanni C, Rubello D, Farsad M et al.18F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur. J. Surg. Oncol.31(7), 792–797 (2005).
   PubMed Web of Science ®Google Scholar
• Simcock B, Neesham D, Quinn M, Drummond E, Milner A, Hicks RJ. The impact of PET/CT in the management of recurrent ovarian cancer. Gynecol. Oncol.103(1), 271–276 (2006).
   PubMed Web of Science ®Google Scholar
• Chung HH, Kang WJ, Kim JW et al. Role of [18F]FDG PET/CT in the assessment of suspected recurrent ovarian cancer: correlation with clinical or histological findings. Eur. J. Nucl. Med. Mol. Imaging34(4), 480–486 (2007).
   Google Scholar
• Mangili G, Picchio M, Sironi S et al. Integrated PET/CT as a first-line re-staging modality in patients with suspected recurrence of ovarian cancer. Eur. J. Nucl. Med. Mol. Imaging34(5), 658–666 (2007).
   Google Scholar
• Thrall MM, DeLoia JA, Gallion H, Avril N. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer. Gynecol. Oncol.105(1), 17–22 (2007).
   PubMed Web of Science ®Google Scholar
• García-Velloso MJ, Jurado M, Ceamanos C et al. Diagnostic accuracy of FDG PET in the follow-up of platinum-sensitive epithelial ovarian carcinoma. Eur. J. Nucl. Med. Mol. Imaging34(9), 1396–1405 (2007).
   Google Scholar
• Sebastian S, Lee SI, Horowitz NS et al. PET-CT vs. CT alone in ovarian cancer recurrence. Abdom. Imaging33(1), 112–118 (2008).
   Google Scholar
• Sheng XG, Zhang XL, Fu Z et al. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma]. Zhonghua Fu Chan Ke Za Zhi42(7), 460–463 (2007).
   Google Scholar
• Soussan M, Wartski M, Cherel P et al. Impact of FDG PET-CT imaging on the decision making in the biologic suspicion of ovarian carcinoma recurrence. Gynecol. Oncol.108(1), 160–165 (2008).
   Google Scholar
• Kim CK, Park BK, Choi JY, Kim BG, Han H. Detection of recurrent ovarian cancer at MRI: comparison with integrated PET/CT. J. Comput. Assist. Tomogr.31(6), 868–875 (2007).
   Google Scholar
• Zimny M, Siggelkow W, Schroder W et al. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography in the diagnosis of recurrent ovarian cancer, Gynecol. Oncol.83, 310–315 (2001).
   PubMed Web of Science ®Google Scholar
• Avril N, Sassen S, Schmalfeldt B et al. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. J. Clin. Oncol.23(30), 7445–7453 (2005).
   PubMed Web of Science ®Google Scholar
• Kurosaki H, Oriuchi N, Okazaki A et al. Prognostic value of FDG-PET in patients with ovarian carcinoma following surgical treatment. Ann. Nucl. Med.20(3), 171–174 (2006).
   Google Scholar
• Smith GT, Hubner KF, McDonald T, Thie JA. Cost analysis of FDG PET for managing patients with ovarian cancer. Clin. Positron Imaging2, 63–70 (1999).
   Google Scholar
• Marchand V, Graveleau J, Lanctin-Garcia C et al. A rare gynecological case of paraneoplastic cerebellar degeneration discovered by FDG-PET. Gynecol. Oncol.105(2), 545–547 (2007).
   Google Scholar
• Komoto D, Nishiyama Y, Yamamoto Y et al. A case of non-Hodgkin’s lymphoma of the ovary: usefulness of 18F-FDG PET for staging and assessment of the therapeutic response. Ann. Nucl. Med.20(2), 157–160 (2006).
   Google Scholar
• Lapela M, Leskinen-Kallio S, Varpula M et al. Metabolic imaging of ovarian tumors with carbon-11-methionine: a PET study. J. Nucl. Med.36(12), 2196–2200 (1995).
   PubMed Web of Science ®Google Scholar
• Belhocine T, De Barsy C, Hustinx R, Willems-Foidart J. Usefulness of 18F-FDG PET in the post-therapy surveillance of endometrial carcinoma. Eur. J. Nucl. Med. Mol. Imaging29(9), 1132–1139 (2002).
   PubMed Web of Science ®Google Scholar
• Saga T, Higashi T, Ishimori T et al. Clinical value of FDG-PET in the follow up of post-operative patients with endometrial cancer. Ann. Nucl. Med.17(3), 197–203 (2003).
   PubMed Web of Science ®Google Scholar
• Chao A, Chang TC, Ng KK et al.18F-FDG PET in the management of endometrial cancer. Eur. J. Nucl. Med. Mol. Imaging33(1), 36–44 (2006).
   PubMed Web of Science ®Google Scholar
• Suzuki R, Miyagi E, Takahashi N et al. Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer. Int. J. Gynecol. Cancer17(4), 890–896 (2007).
   PubMed Web of Science ®Google Scholar
• Park JY, Kim EN, Kim DY et al. Clinical impact of positron emission tomography or positron emission tomography/computed tomography in the posttherapy surveillance of endometrial carcinoma: evaluation of 88 patients. Int. J. Gynecol. Cancer DOI 10.1111/j.1525-1438.2008.01197.x (2008) (Epub ahead of print).
   Google Scholar
• Lapela M, Leskinen-Kallio S, Varpula M et al. Imaging of uterine carcinoma by carbon-11-methionine and PET. J. Nucl. Med.35(10), 1618–1623 (1994).
   PubMed Web of Science ®Google Scholar
• Yoshida Y, Kurokawa T, Sawamura Y et al. The positron emission tomography with F18 17β-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Gynecol. Oncol.104(3), 764–766 (2007).
   PubMed Web of Science ®Google Scholar
• Cohen I, Beyth Y, Altaras MM et al. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies. Gynecol. Oncol.67, 8–15 (1997).
   PubMedGoogle Scholar
• Wilder JL, Shajahan S, Khattar NH et al. Tamoxifen-associated malignant endometrial tumors: pathologic features and expression of hormone receptors estrogen-α, estrogen-β and progesterone: a case controlled study. Gynecol. Oncol.92, 553–558 (2004).
   PubMed Web of Science ®Google Scholar
• Furr BJ, Nicholson RI. The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther.25, 127–205 (1984).
   PubMed Web of Science ®Google Scholar
• Fabian C, Sternson L, El-Serafi M, Cain L, Hearne E. Clinical pharmacology of tamoxifen in patients with breast cancer: correlation with clinical data. Cancer48, 876–882 (1981).
   Google Scholar
• Cohn DE, Dehdashti F, Gibb RK et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. Gynecol. Oncol.85, 179–184 (2002).
   PubMed Web of Science ®Google Scholar
• Rocconi RP, Leath CA 3rd, Johnson WM 3rd, Barnes MN 3rd, Conner MG. Primary lung large cell carcinoma metastatic to the vulva: a case report and review of the literature. Gynecol. Oncol.94(3), 829–831 (2004).
   Google Scholar
• Freudenberg LS, Antoch G, Beyer T, Görges R, Debatin JF, Bockisch A. Diagnosis of labia metastasis by F-18 FDG PET and CT fusion imaging in sarcoma follow-up. Clin. Nucl. Med.28(8), 636–637 (2003).
   Google Scholar
• Lamoreaux WT, Grigsby PW, Dehdashti F et al. FDG-PET evaluation of vaginal carcinoma. Int. J. Radiat. Oncol. Biol. Phys.62(3), 733–737 (2005).
   Google Scholar
• Karlan BY, Hoh C, Tse N, Futoran R, Hawkins R, Glaspy J. Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. Gynecol. Oncol.49(3), 383–388 (1993).
   Google Scholar
• Makhija S, Howden N, Edwards R, Kelley J, Townsend DW, Meltzer CC. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. Gynecol. Oncol.85(1), 53–58 (2002).
   PubMedGoogle Scholar
• Patel PV Cohade C, Chin BB. PET-CT localizes previously undetectable metastatic lesions in recurrent fallopian tube carcinoma. Gynecol. Oncol.87(3), 323–326 (2002).
   Google Scholar
• Kumar R, Alavi A. PET imaging in gynecologic malignancies. Radiol. Clin. North Am.42(6), 1155–1167 (2004).
   PubMed Web of Science ®Google Scholar
• Park JY, Kim EN, Kim DY et al. Comparison of the validity of magnetic resonance imaging and positron emission tomography/computed tomography in the preoperative evaluation of patients with uterine corpus cancer. Gynecol. Oncol.108(3), 486–492 (2008).
   PubMed Web of Science ®Google Scholar
• Basu S, Nair N. Relapse of cervical cancer presenting as symptoms of Collet–Sicard syndrome with metastatic subcutaneous and adrenal deposits. Lancet Oncol.7(7), 610 (2006).
   Google Scholar
• Alavi A, Basu S, Musto A. Molecular imaging with PET: a revolution in medicine. Leadership Medica (2007).
   Google Scholar